广发中证香港创新药ETF发起式联接(QDII)A(019670)申购赎回 |
|
报告期 |
期初总份额(份) |
期末总份额(份) |
期间总申购份额(份) |
期间总赎回份额(份) |
期间净申赎份额(份) |
净申赎比例 |
2024/9/30 |
33,229,200 |
48,012,900 |
21,306,000 |
6,522,370 |
14,783,630 |
44.49% |
2024/6/30 |
16,770,500 |
33,229,200 |
22,895,800 |
6,437,100 |
16,458,700 |
98.14% |
2024/6/30 |
23,695,200 |
33,229,200 |
12,853,900 |
3,319,940 |
9,533,960 |
40.24% |
2024/3/31 |
16,770,500 |
23,695,200 |
10,041,900 |
3,117,160 |
6,924,740 |
41.29% |
2023/12/31 |
10,325,300 |
16,770,500 |
7,071,240 |
626,106 |
6,445,134 |
62.42% |
2023/12/31 |
10,325,300 |
16,770,500 |
7,071,240 |
626,106 |
6,445,134 |
62.42% |
*注:新浪财经提醒:以上数据由合作伙伴提供,仅供参考,交易请以正式公告数据为准。